This week we take a (brief) stop back in time to the beginning of dostarlimab's journey that has ended (for now) in an accelerated approval for rectal cancer that is mismatch repair-deficient or high in micro-satellite instability (MMRd/h-MSI).
Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Fler avsnitt från "OncoPharm"



Missa inte ett avsnitt av “OncoPharm” och prenumerera på det i GetPodcast-appen.








